AI Stock Memo: GTLS - Chart Industries - RankAlpha

GTLS

Rating buyAI Memo

Chart Industries

As of 2025-11-14/Confidence high

Open ticker Back to Memos

Data freshness

AI Memo

As of 2025-11-14 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

buy

Confidence

high

Horizon

—

Key catalyst

Execution risk: supply-chain and delivery delays • 2026-06-30

Expected move: -74%

Biggest risk

Project delays, cost overruns, or cancellations push revenue recognition out and compress margins; weaker hydrogen capex or incentive setbacks could force a multiple re-rating until execution is proven [#10-Q-2024-06-30], [#PR-2025-11-05].

Invalidation

Break below $38 or thesis failure.

What would change my mind?

Chart converts a large portion of its hydrogen backlog within 12–24 months, supply-chain pressures ease, margins recover, and biopharma/LNG mix expands—making the consensus ~$55 target conservative relative to multi-year revenue visibility [#PR-2025-08-12], [#IR-presentation-Q3-2025].

Research note

Recommendation

buy

Confidence

high

As of

2025-11-14

Base target

$55

p=50%

Bull target

$69

p=30%

Bear target

$38

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Quarterly guidance vs.
consensus (beat/miss risk)
Biopharma and LNG demand diversifies revenue

BearKey bullets

Project delays, cost overruns, or cancellations push revenue recognition out and compress margins; weaker hydrogen capex or incentive setbacks could force a multiple re-rating until execution is proven [#10-Q-2024-06-30], [#PR-2025-11-05].

WatchKey bullets

Execution risk: supply-chain and delivery delays

Summary

High-level snapshot

Recommendation

buy

Model confidence

high

Timeframe

Asset

Equity

Trigger

Base case: $55 (p=50%)

Bull/Bear spread: -67% / -82%

Vs latest close: Bull -67% · Base -74% · Bear -82%

Scenario probabilities

Bull Target: $69 (p=30%)Base Target: $55 (p=50%)Bear Target: $38 (p=20%)

Commentary

Company filings and PRs emphasize strong hydrogen-order momentum and backlog growth, prompting cautious optimism among investors; coverage notes sizable award wins but stresses execution and timing risk [#PR-2025-08-12], [#REUT-2025-08-13], [#PR-2025-11-05]. Analyst coverage skews positive with mean targets above the market anchor, reflecting measured optimism contingent on demonstrated execution [#YA-analyst-mean-2025].

As of 2025-11-14 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Quarterly guidance vs. consensus (beat/miss risk)
Biopharma and LNG demand diversifies revenue
Hydrogen backlog growth and large contract awards

Scenarios

Bull Target (Scenario probability)

$69 / p=30% prob

Base Target (Scenario probability)

$55 / p=50% prob

Bear Target (Scenario probability)

$38 / p=20% prob

Price $208 as of 2026-06-02

Nearest Scenario: Bull (∆ 67%)

Targets vs latest close: Bull -67% · Base -74% · Bear -82%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-06-30
Execution risk: supply-chain and delivery delays
MD&A and recent 10-Q flag supply-chain and timing risks that can delay backlog conversion into revenue and compress margins [#10-Q-2024-06-30], [#PR-2025-11-05].
Prob 60.00% • Move -18.00% • Priced-in 30.00%

Short-term Catalysts

Next few weeks

Quarterly guidance vs. consensus (beat/miss risk)
2025-11-05
Earnings releases and investor presentations create near-term volatility if revenue or EPS miss or beat consensus; analysts' mean target sits above the current price [#PR-2025-11-05], [#YA-analyst-mean-2025].
Prob 55% • Move 10% • Priced-in 50%

Long-term Catalysts

Months to a year

Biopharma and LNG demand diversifies revenue
2026-03-31
Investor materials and filings highlight biopharma cryogenic equipment and LNG projects as complementary demand drivers that reduce single-market exposure [#IR-presentation-Q3-2025], [#10-Q-2024-06-30].
Prob 65% • Move 15% • Priced-in 35%
Hydrogen backlog growth and large contract awards
2026-11-01
SEC filings and press releases show backlog growth driven by hydrogen orders; media reports and PRs cite sizable awards that support multi-year revenue visibility [#10-Q-2024-06-30], [#PR-2025-08-12], [#REUT-2025-08-13].
Prob 75% • Move 25% • Priced-in 40%

Risks

No risks

Peers

Symbol	Summary
APD	Air Products — global industrial-gas leader; useful scale and contract-comparison, with less exposure to cryogenic equipment manufacturing [#APD-IR]
LIN	Linde — very large industrial-gases and engineering footprint; greater scale and merchant-gases exposure versus Chart's project-driven cryogenic niche [#LIN-IR]

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Analysis date: 2025-11-14